Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TRDA

Entrada Therapeutics Inc

Feb 06 • 04:00PM ET

10.60

+0.53 5.26 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA REGN PFE GILD BNTX NVAX VRTX SRPT INCY RNA

| Held by: VTI IWM VXF IWN IBB VTWO SCHA IWC AVSC DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.50	Insider Own	43.12%	Shs Outstand	38.22M	Perf Week	-7.34%
Market Cap	405.12M	Forward P/E	-	EPS next Y	-4.19	Insider Trans	-1.21%	Shs Float	21.74M	Perf Month	-1.40%
Enterprise Value	130.68M	PEG	-	EPS next Q	-1.17	Inst Own	48.89%	Short Float	3.95%	Perf Quarter	52.74%
Income	-103.45M	P/S	6.59	EPS this Y	-310.10%	Inst Trans	-3.10%	Short Ratio	3.53	Perf Half Y	100.00%
Sales	61.52M	P/B	1.19	EPS next Y	-18.80%	ROA	-21.39%	Short Interest	0.86M	Perf YTD	3.11%
Book/sh	8.91	P/C	1.24	EPS next 5Y	-	ROE	-27.11%	52W High	14.02 -24.39%	Perf Year	-24.23%
Cash/sh	8.55	P/FCF	-	EPS past 3/5Y	- -	ROIC	-26.61%	52W Low	4.93 115.01%	Perf 3Y	-12.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	93.11%	Volatility	8.08% 7.10%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.12	EPS Y/Y TTM	-248.91%	Oper. Margin	-194.50%	ATR (14)	0.74	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.08	Sales Y/Y TTM	-71.42%	Profit Margin	-168.16%	RSI (14)	47.47	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.08	EPS Q/Q	-208.16%	SMA20	-3.36%	Beta	-0.08	Target Price	18.00
Payout	0.00%	Debt/Eq	0.15	Sales Q/Q	-91.75%	SMA50	-0.85%	Rel Volume	0.76	Prev Close	10.07
Employees	183	LT Debt/Eq	0.14	Earnings	Nov 06 BMO	SMA200	35.70%	Avg Volume	243.36K	Price	10.60
IPO	Oct 29, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-12.77% -81.34%	Trades		Volume	184,901	Change	5.26%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Oppenheimer	Outperform	$21
Dec-06-24	Initiated	ROTH MKM	Buy	$29
Jan-05-24	Initiated	Oppenheimer	Outperform	$22
Apr-03-23	Initiated	H.C. Wainwright	Buy	$25

Feb-05-26 06:00PM	Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates (Zacks) -6.93% +5.26%
Feb-04-26 07:40AM	Techne (TECH) Beats Q2 Earnings and Revenue Estimates (Zacks) -8.23%
07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-09-26 07:16AM	Entrada Therapeutics reports progress across development portfolio (TipRanks)
Jan-08-26 07:00AM	Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases (GlobeNewswire)
08:45AM	Loading…
Dec-30-25 08:45AM	The Biggest IPO of the Year Prompts Huge Insider Buy (24/7 Wall St.)
Dec-17-25 07:00AM	Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 08:30AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-30-25 08:10AM	Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-29-25 07:46AM	Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last? (Zacks) -6.26%
Oct-28-25 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-05-25 07:00AM	Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program (GlobeNewswire)
Sep-02-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:15AM	Loading…
Aug-06-25 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 10:15AM	Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) -11.45%
Jun-03-25 07:00AM	Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire)
Jun-02-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.11%
May-29-25 11:10AM	Entradas Phase I/II trial of DMD treatment authorised to begin in EU (Clinical Trials Arena)
May-28-25 07:00AM	Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
May-08-25 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.64%
07:00AM	Entrada Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
08:00AM	Arvinas, Entrada cut staff; Merck builds US hub for Keytruda (BioPharma Dive)
Apr-29-25 10:01AM	Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-10-25 09:30AM	Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? (Zacks) -5.08%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-25-25 10:03AM	Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment (Clinical Trials Arena) -5.79%
07:00AM	Loading…
Mar-24-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
Feb-27-25 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 06:11AM	AstraZenecas next breast cancer drug; Madrigals accelerating MASH launch (BioPharma Dive)
Feb-25-25 01:05PM	FDA removes clinical hold on Entradas Duchenne therapy (Clinical Trials Arena) -5.68%
Feb-24-25 07:00AM	Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 (GlobeNewswire)
Feb-12-25 07:58AM	Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-04-25 07:19AM	Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment (Clinical Trials Arena)
Feb-03-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy (GlobeNewswire)
Jan-30-25 04:05PM	Azenta Announces the Election of Dipal Doshi to its Board of Directors (PR Newswire)
Dec-18-24 07:00AM	Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.32%
Dec-07-24 05:25AM	Roth MKM starts overlooked Entrada Therapeutics with Buy rating (TipRanks)
Nov-25-24 08:50AM	Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-05-24 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-09-24 07:00AM	Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-24-24 07:00AM	Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development (GlobeNewswire) +5.70%
Sep-17-24 08:30AM	ashibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors (Business Wire)
Sep-06-24 07:00AM	Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program (GlobeNewswire)
Aug-13-24 08:20AM	Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates (Zacks) +11.26%
07:00AM	Entrada Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 09:55AM	Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High? (Zacks) +5.75%
Jul-12-24 09:33AM	Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last? (Zacks)
Jun-24-24 07:15AM	Entrada Therapeutics Announces $100 Million Registered Direct Offering (GlobeNewswire)
06:00AM	Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-03-24 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 09:55AM	Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet (Zacks)
May-20-24 05:32PM	Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing (MT Newswires)
May-16-24 07:02PM	Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
04:35PM	Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing (MT Newswires)
07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-07-24 01:53PM	TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Entrada Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-10-24 03:29PM	Insiders are Piling into These 5 Healthcare Stocks in 2024 (Insider Monkey) -5.72%
Apr-04-24 02:00PM	The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. (PR Newswire)
Mar-27-24 01:27AM	Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
Mar-15-24 05:31AM	Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials (GuruFocus.com)
Mar-13-24 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.76%
Feb-07-24 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-29-24 08:14AM	Time to Pull the Trigger, Says Oppenheimer About These 3 Stocks (TipRanks)
Jan-03-24 07:00AM	Entrada Therapeutics Promotes Nathan J. Dowden to President (GlobeNewswire) -9.03%
Dec-28-23 07:01AM	Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares (GuruFocus.com)
Nov-23-23 11:47AM	Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug (Zacks)
Nov-22-23 07:00AM	Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -31.85%
Nov-07-23 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +8.63%
08:06AM	Entrada Therapeutics Inc (TRDA) Reports Q3 2023 Earnings, Net Income of $35.5 Million (GuruFocus.com)
07:00AM	Entrada Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-12-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -9.47%
Sep-21-23 07:00AM	Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-16-23 01:01AM	Insider Sell: Entrada Therapeutics Inc CEO Dipal Doshi Sells 1,000 Shares (GuruFocus.com)
Sep-07-23 07:00AM	Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community (GlobeNewswire) +5.48%
Aug-29-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Entrada Therapeutics Appoints Gina Chapman to its Board of Directors (GlobeNewswire)
Aug-08-23 08:40AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +10.47%
07:00AM	Entrada Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 06:36AM	Entrada Therapeutics (NASDAQ:TRDA) pulls back 16% this week, but still delivers shareholders notable 33% return over 1 year (Simply Wall St.)
Aug-01-23 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-21-23 06:43AM	New Strong Buy Stocks for July 21st (Zacks)
Jun-06-23 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire) +6.54%
May-15-23 06:03AM	Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Estimates (Simply Wall St.)
May-13-23 08:03AM	Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now (Simply Wall St.)
May-10-23 07:00AM	Entrada Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-30-23 10:26AM	We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Apr-04-23 07:00AM	Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors (GlobeNewswire) -5.07%
Mar-29-23 07:00AM	Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference (GlobeNewswire)
Mar-08-23 06:02AM	Entrada Therapeutics, Inc. (NASDAQ:TRDA) Is About To Turn The Corner (Simply Wall St.) +5.94%
Mar-06-23 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 07:00AM	Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-09-23 07:00AM	Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
Jan-09-23 07:00AM	Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable (GlobeNewswire) +6.95%

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The company's oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 21 '25	Sale	9.98	8,910	88,932	110,026	Nov 24 04:30 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 20 '25	Buy	9.07	28,867	261,846	4,691,392	Nov 24 04:09 PM
KORY WENTWORTH	Officer	Nov 21 '25	Proposed Sale	9.17	8,910	81,705		Nov 21 04:45 PM
PARMAR KUSH	Director	Nov 14 '25	Sale	8.80	200,000	1,760,000	2,963,066	Nov 18 04:36 PM
5AM Ventures V, L.P.	10% Owner	Nov 14 '25	Sale	8.80	200,000	1,760,000	2,963,066	Nov 18 04:34 PM
5AM Ventures V, L.P.	Affiliated Stockholder	Nov 14 '25	Proposed Sale	8.80	200,000	1,760,664		Nov 14 04:30 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 12 '25	Buy	7.76	100,736	781,638	4,664,924	Nov 12 05:34 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 11 '25	Buy	7.50	46,434	348,193	4,572,549	Nov 12 05:34 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 10 '25	Buy	7.21	30,874	222,756	4,529,969	Nov 12 05:34 PM
PARMAR KUSH	Director	Jul 09 '25	Sale	7.50	27,000	202,554	1,093,313	Jul 11 05:27 PM
5AM Ventures V, L.P.	10% Owner	Jul 09 '25	Sale	7.50	20,065	150,528	3,163,066	Jul 11 05:25 PM
5AM Ventures V, L.P.	10% Owner	Jul 09 '25	Sale	7.50	6,935	52,026	1,093,313	Jul 11 05:25 PM
5AM Opportunities I, L.P.	Director	Jul 09 '25	Proposed Sale	7.50	6,935	52,025		Jul 09 05:04 PM
5AM Ventures V, L.P.	Director	Jul 09 '25	Proposed Sale	7.50	20,065	150,528		Jul 09 05:02 PM
PARMAR KUSH	Director	Jun 27 '25	Sale	6.91	75,000	518,250	1,113,092	Jul 01 08:33 PM
PARMAR KUSH	Director	Jul 01 '25	Sale	7.12	25,000	178,065	1,100,248	Jul 01 08:33 PM
PARMAR KUSH	Director	Jun 30 '25	Sale	6.81	25,000	170,318	1,106,670	Jul 01 08:33 PM
5AM Ventures V, L.P.	10% Owner	Jun 27 '25	Sale	6.91	55,735	385,129	3,220,287	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jun 27 '25	Sale	6.91	19,265	133,121	1,113,092	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jul 01 '25	Sale	7.12	18,578	132,324	3,183,131	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jun 30 '25	Sale	6.81	18,578	126,566	3,201,709	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jul 01 '25	Sale	7.12	6,422	45,741	1,100,248	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jun 30 '25	Sale	6.81	6,422	43,751	1,106,670	Jul 01 08:32 PM
5AM Ventures V, L.P.	Director	Jul 01 '25	Proposed Sale	7.12	18,578	132,324		Jul 01 05:03 PM
5AM Opportunities I, L.P.	Director	Jul 01 '25	Proposed Sale	7.12	6,422	45,737		Jul 01 05:01 PM
5AM Opportunities I, L.P.	Director	Jun 30 '25	Proposed Sale	6.81	6,422	43,751		Jun 30 05:09 PM
5AM Ventures V, L.P.	Director	Jun 30 '25	Proposed Sale	6.81	18,578	126,566		Jun 30 05:06 PM
5AM Opportunities I, L.P.	Director	Jun 27 '25	Proposed Sale	6.91	19,265	133,121		Jun 27 05:05 PM
5AM Ventures V, L.P.	Director	Jun 27 '25	Proposed Sale	6.91	55,735	385,129		Jun 27 05:03 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Apr 03 '25	Option Exercise	2.10	11,134	23,381	120,670	Apr 04 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 17 '25	Sale	10.67	1,784	19,035	109,536	Mar 19 04:32 PM
KORY WENTWORTH	Officer	Mar 17 '25	Proposed Sale	10.81	1,784	19,285		Mar 17 04:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRDA

Entrada Therapeutics Inc

Upgrade your FINVIZ experience